On March 28, 2023,
Evercore ISI Group
initiated coverage of Astria Therapeutics with
a Outperform recommendation.
Analyst Price Forecast Suggests 114.24% Upside
As of March 27, 2023,
the average one-year price target for Astria Therapeutics is $26.18.
The forecasts range from a low of $20.20 to a high of $33.60.
The average price target represents an increase of 114.24% from its latest reported closing price of $12.22.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Astria Therapeutics
is $0MM, a decrease of 100.00%.
The projected annual non-GAAP EPS
is -$2.99.
What are Large Shareholders Doing?
Perceptive Advisors
holds 2,189K shares
representing 7.82% ownership of the company.
In it’s prior filing, the firm reported owning 1,281K shares, representing
an increase
of 41.48%.
The firm
increased
its portfolio allocation in ATXS by 172.35% over the last quarter.
Fairmount Funds Management
holds 1,901K shares
representing 6.79% ownership of the company.
In it’s prior filing, the firm reported owning 912K shares, representing
an increase
of 52.05%.
The firm
increased
its portfolio allocation in ATXS by 210.01% over the last quarter.
Deep Track Capital
holds 1,817K shares
representing 6.49% ownership of the company.
Vivo Capital
holds 1,681K shares
representing 6.01% ownership of the company.
In it’s prior filing, the firm reported owning 1,000K shares, representing
an increase
of 40.52%.
The firm
increased
its portfolio allocation in ATXS by 188.79% over the last quarter.
Cormorant Asset Management
holds 1,650K shares
representing 5.90% ownership of the company.
In it’s prior filing, the firm reported owning 1,200K shares, representing
an increase
of 27.27%.
The firm
increased
its portfolio allocation in ATXS by 116.82% over the last quarter.
What is the Fund Sentiment?
There are 93 funds or institutions reporting positions in Astria Therapeutics.
This is an increase
of
22
owner(s) or 30.99% in the last quarter.
Average portfolio weight of all funds dedicated to ATXS is 0.47%,
an increase
of 181.06%.
Total shares owned by institutions increased
in the last three months by 124.22% to 22,204K shares.
The put/call ratio of ATXS is 0.69, indicating a
bullish
outlook.
Astria Therapeutics Background Information
(This description is provided by the company.)
Astria Therapeutics’ dedicated and passionate team is devoted to bringing life-changing therapies to patients and families impacted by HAE and rare and niche allergic and immunological diseases.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
